• Geoff D Braatvedt, Tim Cundy, Michael Crooke, Chris Florkowski, Jim I Mann, Helen Lunt, Rod Jackson, Brandon Orr-Walker, Timothy Kenealy, and Paul L Drury.
• Department of Medicine, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. g.braatvedt@auckland.ac.nz
• N. Z. Med. J. 2012 Sep 21; 125 (1362): 70-80.

AbstractIn New Zealand laboratories the measurement of glycated haemoglobin (HbA1c) for diagnosis of diabetes is now only reported in SI units of mmol/mol. HbA1c is now recommended as the preferred test to diagnose diabetes in most circumstances. The requirement for a second positive test in asymptomatic individuals is retained. An HbA1c greater than and equal to 50 mmol/mol (repeated on a second occasion in asymptomatic patients) is diagnostic of diabetes and a value less than and equal to 40 mmol/mol represents normal glucose tolerance. For patients with an initial HbA1c result of 41-49 mmol/mol, cardiovascular risk assessment and lifestyle interventions are recommended with repeat HbA1c screening in 6-12 months. For patients whose HbA1c is less than and equal to 40 mmol/mol, repeat screening (including for CVD risk) at intermittent intervals is recommended as per published guidelines.

20 keywords...

hide…